Fillable Drug Prior Authorization Form Humira (adalimumab) (Great-West Life Insurance for Personal, Group & Benefits in Canada)

Fill Online, Printable, Fillable, Blank Drug Prior Authorization Form Humira (adalimumab) (Great-West Life Insurance for Personal, Group & Benefits in Canada) Form

Use Fill to complete blank online GREAT-WEST LIFE INSURANCE FOR PERSONAL, GROUP & BENEFITS IN CANADA pdf forms for free. Once completed you can sign your fillable form or send for signing. All forms are printable and downloadable.

Drug Prior Authorization Form Humira (adalimumab) (Great-West Life Insurance for Personal, Group & Benefits in Canada)

On average this form takes 86 minutes to complete

The Drug Prior Authorization Form Humira (adalimumab) (Great-West Life Insurance for Personal, Group & Benefits in Canada) form is 9 pages long and contains:

  • 0 signatures
  • 10 check-boxes
  • 338 other fields

Country of origin: CANADA
File type: PDF

Use our library of forms to quickly fill and sign your Great-West Life Insurance for Personal, Group & Benefits in Canada forms online.

BROWSE GREAT-WEST LIFE INSURANCE FOR PERSONAL, GROUP & BENEFITS IN CANADA FORMS

Related forms
Fill has a huge library of thousands of forms all set up to be filled in easily and signed.
Fill in your chosen form
Sign the form using our drawing tool
Send to someone else to fill in and sign.
find another form
 
Page 1 of 9
(Continued on next page)
Plan Member’s signature: Date:
This document contains both information and form fields. To read information, use the Down Arrow from a form field.
M6453(HUMIRA)-1/20
© The Canada Life Assurance Company, all rights reserved. Canada Life and design are trademarks of The Canada Life Assurance Company.
Any modification of this document without the express written consent of Canada Life is strictly prohibited.
Drug Prior Authorization Form
Humira (adalimumab)
The purpose of this form is to obtain information required to assess your drug claim.
IMPORTANT: Please answer all questions. Your claim assessment will be delayed if this form is incomplete or contains errors.
Any costs incurred for the completion of this form are the responsibility of the plan member/patient.
Canada Life recognizes and respects the importance of privacy. Personal information collected is used for the purposes of
assessing eligibility for this drug and for administering the group benets plan. For a copy of our Privacy Guidelines, or if you have
questions about Canada Life’s personal information policies and practices (including with respect to service providers), r
efer to
www.canadalife.com or write to Canada Life’s Chief Compliance Ofcer.
I authorize Canada Life, any healthcare provider, my plan administrator, any insurance or reinsurance company, administrators of
government benets or patient assistance programs or other benets programs, other organizations, or service pr
oviders working with
Canada Life or any of the above, located inside or outside Canada, to exchange personal information when relevant and necessary for
these purposes. I understand that personal information may be subject to disclosure to those authorized under applicable law within
or outside Canada.
I acknowledge that the personal information is needed to assess eligibility for this drug and to administer the group benets plan.
I acknowledge that providing consent will help Canada Life to assess my claim and that refusing to consent may result in delay or
denial of my claim. Canada Life reserves the right to audit the information pr
ovided on this form at any time and this consent extends
to any audit of my claim. This consent may be revoked by me at any time by sending written instruction to that effect.
I also consent to the use of my personal information for Canada Life and its afliates’ internal data management and analytics purposes.
If the patient is a person other than myself, I conrm that the patient has given their consent to provide their personal information and
for Canada Life to use and disclose it as set out above.
I certify that the information given below is true, correct, and complete to the best of my knowledge. Failure to provide true, correct
and complete information on this form could result in revocation of any approval decision, a requir
ement to repay paid claims or other
appropriate action.
Form Completion Instructions:
1. Complete “Patient Information” sections.
2. Have the prescribing physician complete the “Physician Information” sections.
3. Send all pages of the completed form to us by mail, fax or email as noted below.
Note: As email is not a secure medium, any person with concerns about their prior authorization form/medical information being
intercepted by an unauthorized party is encouraged to submit their form by other means.
Mail to: The Canada Life Assurance Company
Drug Claims Management
PO Box 6000
Winnipeg MB R3C 3A5
Fax to: The Canada Life Assurance Company
Fax 1-204-946-7664
Attention: Drug Claims Management
Email to: cldrug.services@canadalife.com
Attention: Drug Claims Management
For additional information regarding Prior Authorization and Health Case Management, please visit our Canada Life website
at www.canadalife.com or contact Group Customer Contact Services at 1-800-957-9777.
(Continued on next page)
M6453(HUMIRA)-1/20
Page 2 of 9
Humira (adalimumab)
Plan Member:
Plan Name:
Patient Date of Birth (DD/MM/YYYY):
If yes, please provide email address:
Please indicate preferred contact number and if there are any times when telephone contact with you about your claim would be most convenient.
Plan Number:
Address (number, street, city, province, postal code):
Plan Member ID Number:
Patient Name:
(please print)
If Yes, a) indicate start date (DD/MM/YYYY):
b) coverage provided by:
(if coverage is not provided by Canada Life please provide pharmacy print-out showing purchase of this drug)
1. Patient assistance program patient ID Number:
Contact Name: Phone Number:
–
Patient Information
Plan Member Information Complete all sections of this page
May we contact you by email? (Note that some correspondence may still need to be sent by regular mail).
Yes No
Tell us if you have been on this drug before
Is the patient currently on, or previously been on this drug? Yes No
Tell us if you have coverage with any other benefits plan
Does the patient have drug coverage under any other group benets plan?
If Yes, name of other Insurance Company:
If other plan is with Canada Life, tell us the plan and ID number:
Name of plan member:
Relationship to patient:
Provide details and attach documentation of acceptance or decline:
Yes No
Tell us about any Provincial or other coverage you may have
Does the patient have coverage under a provincial program or from any other source? Yes No
If Yes, name of program or other source:
Provide details and attach documentation of acceptance or decline:
Is the patient currently receiving disability benets for the condition for which this drug has been prescribed?
Yes No
Tell us about any Patient Assistance Program you might be enrolled in
Has the patient enrolled in the patient assistance program for this drug? Yes No
If Yes, please provide the following information:
2. Patient assistance program contact person name and phone number:
M6453(HUMIRA)-1/20
Page 3 of 9
Humira (adalimumab)
Name of prescribing physician:
Specialty:
Address (number, street, city, province, postal code):
Telephone Number (including area code): Fax Number (including area code):
(please print)
(include date of initial diagnosis) (MM/YYYY):
Dosage and Regimen:
Dosage and Regimen:
Physician Information
Note to Physician: In order to assess a patient’s claim for this drug, we require detailed information on the patient’s
prescription drug history as requested below.
Attach extra information if necessary. GENETIC TEST RESULTS ARE NOT REQUIRED
Physician’s Information
1. Health Canada indication
Ankylosing Spondylitis
Crohn’s Disease
Hidradenitis Suppurativa
Non-infectious Uveitis
Polyarticular Juvenile Idiopathic Arthritis
Psoriasis
Psoriatic Arthritis
Rheumatoid Arthritis
Ulcerative Colitis
Other (approved by Health Canada):
Other (prescribed use is not approved by Health Canada):
40mg every other week
Pediatric: 160mg week 0, 80mg on week 2, 20mg on week 4 and every other week thereafter
160mg week 0, 80mg on week 2, then 40mg on week 4 and every other week thereafter
Renewal: 20mg OR 40mg every other week
160mg week 0, 80mg on week 2, then 40mg on week 4 and weekly thereafter
Renewal: 40mg weekly
80mg week 0, 40mg week 1 and every other week thereafter
Renewal: 40mg every other week
80mg on week 0, then 40mg on week 1 and every other week thereafter
mg every other week
80mg on week 0, then 40mg on week 1 and every other week thereafter
Renewal: 40mg every other week
40mg every other week
40mg every other week
160mg week 0, 80mg on week 2, then 40mg on week 4 and every other week thereafter
Renewal: 40mg every other week
Any other dosage regimen and rationale for alternate dosing:
Complete questions 1-4 and Physician’s information
Complete questions 1-5 and Other condition (Health Canada approved)
Complete questions 1-5 and Off-label use
Page 4 of 9
Physician Information
Humira (adalimumab)
(Continued on next page)
Patient’s weight:
kg (for weight-based dosing)
Date determined (MM/YYYY):
2. What is the anticipated duration of treatment with this drug?
4. Please provide medical rationale why Humira has been prescribed instead of an alternate drug in the same therapeutic class:
Clinical details:
Clinical details:
Clinical details:
Provide diagnostic imaging report of SI joint with interpretation Current BASDAI score and date (DD/MM/YYYY)
If yes, indicate length and time present:
Clinical details:
Clinical details:
Clinical details:
Physician’s Information (continued) (please print)
3. Where will treatment be administered? Home Physician’s Ofce Private clinic Hospital in-patient Hospital out-patient
5. Drug and Treatment History – must be completed for every request. If coverage for these drugs was not provided by Canada Life, please
submit a pharmacy printout for the last 12 months.
Drug(s) and Treatment(s)
past and present
Dosing Regimen Start Date
(DD/MM/YYYY)
End Date
(DD/MM/YYYY)
Clinical Results/Outcome
Failure Intolerance Other
Failure Intolerance Other
Failure Intolerance Other
Ankylosing Spondylitis
Back pain present? Yes No
Drug(s) and Treatment(s)
past and present
Dosing Regimen Start Date
(DD/MM/YYYY)
End Date
(DD/MM/YYYY)
Clinical Results/Outcome
Failure Intolerance Other
Failure Intolerance Other
Failure Intolerance Other
If coverage for these drugs was not provided by Canada Life, please submit a pharmacy printout for the last 12 months.
M6453(HUMIRA)-1/20
Page 5 of 9
Physician Information
Humira (adalimumab)
Please state the current Hurley stage of patient’s HS lesions:
What is the patient’s current total abscess and inammatory nodule (AN) count?
Clinical details:
Clinical details:
Clinical details:
Endo Subscore:
Current HBI: (DD/MM/YYYY)
OR Current CDAI: (DD/MM/YYYY)
ESR: (DD/MM/YYYY)
CRP: (DD/MM/YYYY)
Site of the disease and complications of Ulcerative Colitis or Crohn’s
Disease:
Hidradenitis Suppurativa
Moderate to severe
Drug(s) and Treatment(s)
past and present
Dosing Regimen Start Date
(DD/MM/YYYY)
End Date
(DD/MM/YYYY)
Clinical Results/Outcome
Failure Intolerance Other
Failure Intolerance Other
Failure Intolerance Other
If coverage for these drugs was not provided by Canada Life, please submit a pharmacy printout for the last 12 months.
Inflammatory Bowel Disease
Was Humira started while the patient was in the hospital? Yes No
Ulcerative Colitis
Moderate Severe
Current MAYO score ≥6: Yes No
Crohn’s Disease
Moderate Severe
Required Documentation for both Ulcerative Colitis and Crohn’s
Disease provide:
Required for all applications:
For inammatory Bowel Disease (Ulcerative Colitis or Crohn’s Disease): include daily steroid dose on medical chart.
Non-Infectious Uveitis
Check all that apply:
Patient has active disease and has had an inadequate response to at least 2 weeks of high dose oral corticosteroids
Patient is dependent on oral corticosteroids, which have been used for at least 4 weeks, to maintain inactive disease
Patient is contraindicated to corticosteroids. Provide details:
Patient has failed or has contraindications to an ant-metabolic or calcineurin inhibitor treatment
M6453(HUMIRA)-1/20
Page 6 of 9
Physician Information
Humira (adalimumab)
%BSA Areas of Body involved
Thickness of plaques
Current results and date of both of the following (DD/MM/YYYY)
DLQI PASI
Clinical details:
Clinical details:
Clinical details:
Clinical details:
Clinical details:
If yes, please explain:
Polyarticular juvenile idiopathic arthritis
Is the patient’s disease moderately to severely active? Yes No
Will the patient use Humira in combination with methotrexate? Yes No
Is the patient unable to receive or has a clinical contraindication to methotrexate? Yes No
Has the patient failed at least a 12-week trial of a DMARD? Yes No
Psoriasis
Drug(s) and Treatment(s)
past and present
Dosing Regimen Start Date
(DD/MM/YYYY)
End Date
(DD/MM/YYYY)
Clinical Results/Outcome
Methotrexate
Failure Intolerance Other
Acitretin
Failure Intolerance Other
Cyclosporine
Failure Intolerance Other
Failure Intolerance Other
Failure Intolerance Other
If coverage for these drugs was not provided by Canada Life, please submit a pharmacy printout for the last 12 months.
M6453(HUMIRA)-1/20
Page 7 of 9
Physician Information
Humira (adalimumab)
Swollen joint count Results of the following and date (DD/MM/YYYY)
ESR
CRP
Current results and date of one of the following (DD/MM/YYYY)
CDAI DAS28 HAQ
Clinical details:
Clinical details:
Clinical details:
Clinical details:
Clinical details:
Clinical details:
Psoriatic Arthritis
Drug(s) and Treatment(s)
past and present
Dosing Regimen Start Date
(DD/MM/YYYY)
End Date
(DD/MM/YYYY)
Clinical Results/Outcome
Methotraxate
Failure Intolerance Other
Leunomide
Failure Intolerance Other
Sulfasalazine
Failure Intolerance Other
Failure Intolerance Other
Failure Intolerance Other
Failure Intolerance Other
If coverage for these drugs was not provided by Canada Life, please submit a pharmacy printout for the last 12 months.
M6453(HUMIRA)-1/20
Page 8 of 9
Physician Information
Humira (adalimumab)
Clinical details:
Clinical details:
Clinical details:
Clinical details:
Clinical details:
Clinical details:
Please provide any relevant information related to the disease and attach supporting documentation.
Swollen joint count Results of the following and date (DD/MM/YYYY)
ESR
CRP
Current results and date of one of the following (DD/MM/YYYY)
CDAI DAS28 HAQ
Rheumatoid Arthritis
Drug(s) and Treatment(s)
past and present
Dosing Regimen Start Date
(DD/MM/YYYY)
End Date
(DD/MM/YYYY)
Clinical Results/Outcome
Methotrexate
Failure Intolerance Other
Leunomide
Failure Intolerance Other
Sulfasalazine
Failure Intolerance Other
Failure Intolerance Other
Failure Intolerance Other
Failure Intolerance Other
If coverage for these drugs was not provided by Canada Life, please submit a pharmacy printout for the last 12 months.
Other condition (Health Canada approved)
M6453(HUMIRA)-1/20
M6453(HUMIRA)-1/20
Page 9 of 9
Physician Information
Humira (adalimumab)
Provide any pertinent medical history or information to support this off-label request.
If this is a renewal request, provide documentation showing efcacy since previous request.
Physician’s Signature: Date:
License Number:
Off-label use
Questions 1-5 must be completed.
Is there clinical evidence supporting the off-label use of this drug? Yes No
Provide clinical literature / studies to support the request for off-label use, such as:
• At least two Phase II or two Phase III clinical trials showing consistent results of efcacy; and
• Published recommendations in evidence-based guidelines supporting its use.
Provide medical rationale why this drug has been prescribed off-label instead of an alternate drug with an approved indication for this condition.
Note for Physician: To be eligible for reimbursement, Canada Life may require your patient to purchase a drug requiring prior
authorization from a pharmacy designated by Canada Life. If applicable, a health case manager will contact you with further
information.
I certify that the information provided is true, correct, and complete.
It is important to provide the requested information in detail to help avoid delay in assessing claims for the above drug. This form may
be subject to audit. The completed form can be returned to Canada Life by mail, fax, or email.
Note: As email is not a secure medium, any person with concerns about their prior authorization form/medical information being
intercepted by an unauthorized party is encouraged to submit their form by other means.
Mail to: The Canada Life Assurance Company
Drug Claims Management
PO Box 6000
Winnipeg MB R3C 3A5
Fax to: The Canada Life Assurance Company
Fax 1-204-946-7664
Attention: Drug Claims Management
Email to: cldrug.services@canadalife.com
Attention: Drug Claims Management
Clear
Download
Save PDF to desktop
Email
Email completed PDF
Send for Signing
Email for others to sign
Print
Print document
Choose a Field
Click on a field and
select the person that should complete it
Want to add a signature?
You can add a signature field
and assign it to someone else
to sign
Choose a Field
Click on a field and
select the person that should complete it

Drug Prior Authorization Form Humira (adalimumab) (Great-West Life Insurance for Personal, Group & Benefits in Canada)

This document is locked as it has been sent for signing.

You have successfully completed this document.

Other parties need to complete fields in the document. You will recieve an email notification when the document has been completed by all parties.

This document has been signed by all parties.

Completed 24 December 2020

Message

View Audit Log
Print With Audit Log
Duplicate Document